4-[2-[(Z)-indol-3-ylidenemethyl]hydrazinyl]-6-morpholin-4-yl-N-phenyl-1,3,5-triazin-2-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-[2-[(Z)-indol-3-ylidenemethyl]hydrazinyl]-6-morpholin-4-yl-N-phenyl-1,3,5-triazin-2-amine
• 化学式: C₂₂H₂₂N₈O
• 分子量: 414.5
• InChiKey: DQYBWFGQECIOAR-FOCLMDBBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  99.6
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• AUTOPHAGY MODULATORS FOR USE IN TREATING CANCER
  申请人：The United States of America,as represented by the Secretary,Department of Health and Human Services

  公开号：US20200369649A1

  公开（公告）日：2020-11-26

  Disclosed is method for treating cancer in a mammal, comprising administering to a mammal in need thereof a compound of the formula: wherein R 1 , R 2 , and R 3 are as defined herein, wherein the cancer is an autophagy-dependent cancer, in an amount sufficient to induce autophagy in the cell and cause the death of cancer cells. Also disclosed is a method for selectively killing cancer cells in a patient afflicted with cancer, comprising administering to the mammal, wherein the cancer cells are autophagy-dependent cancer cells, in an amount sufficient to induce autophagy in the cells and cause the death of the cancer cells.
• [EN] AUTOPHAGY MODULATORS FOR TREATING NEURODEGENERATIVE DISEASES<br/>[FR] MODULATEURS D'AUTOPHAGIE POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：US HEALTH

  公开号：WO2016204988A1

  公开（公告）日：2016-12-22

  Disclosed is a method of decreasing an amount of protein aggregate in a cell comprising contacting the cell with a compound of the formula (I): wherein R1, R2, and R3 are as defined herein, in an amount sufficient to induce autophagy in the cell and cause the degradation of the protein aggregate within the cell. Also disclosed is a method of treating or preventing a condition, syndrome, or disease in a mammal in need thereof, wherein the condition, syndrome, or disease is selected from Huntington's disease, Alzheimer's disease, Parkinson's disease, Hutchinson-Gilford progeria syndrome, Niemann-Pick type C disease, spinobulbar muscular atrophy (Kennedy disease), dentatorubral-pallidoluysian atrophy (Haw-River syndrome), spinocerebellar ataxia type 1, spinocerebellar ataxia type 2, spinocerebellar ataxia type 3, spinocerebellar ataxia type 6, and spinocerebellar ataxia type 7, comprising administering to the mammal the compound.
• [EN] COMBINED PIKFYVE AND P38 MAP KINASE INHIBITION FOR TREATING CANCER<br/>[FR] INHIBITION COMBINÉE DE PIKFYVE ET DE KINASE MAP P38 POUR LE TRAITEMENT DU CANCER
  申请人：US HEALTH

  公开号：WO2021086912A1

  公开（公告）日：2021-05-06

  Disclosed is a method for treating a cancer in a mammal in need thereof, comprising administering to the mammal a combination of effective amount of an autophagy inhibitor and a p38 mitogen-activated protein kinase (p38 MAPK) inhibitor, wherein the effective amount is sufficient to reduce or inhibit proliferation of cancer cells or to cause the death of cancer cells.